Related Experiment Video

Updated: Jun 25, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

[Mild cognitive impairment: the neuropsychological characteristics of the different subtypes]

M L Migliacci1, D Scharovsky, S E Gonorazky

  • 1Hospital Privado de Comunidad, Mar de Plata, Buenos Aires, Argentina. leonelmigliacci@gmail.com

Revista De Neurologia
|March 6, 2009
PubMed
Abstract

Insights

The most common mild cognitive impairment (MCI) subtype is MCI-multiple domain type (MCI-MDT). More extensive neuropsychological evaluations improve classification accuracy for MCI subtypes, particularly MCI-MDT and MCI-single domain non-amnestic (MCI-MNOA).

Area of Science:

  • Neuroscience
  • Gerontology
  • Cognitive Psychology

Context:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
  • Accurate classification of MCI subtypes is crucial for understanding disease progression and developing targeted interventions.
  • Previous studies have varied in their methodologies for classifying MCI subtypes.

Purpose:

  • To determine the prevalence of different mild cognitive impairment (MCI) subtypes within a specific population.
  • To characterize the neuropsychological profiles associated with each MCI subtype.
  • To assess how the length and comprehensiveness of neuropsychological examinations influence MCI subtype classification.

Summary:

  • A study of 204 patients diagnosed with MCI found that MCI-multiple domain type (MCI-MDT) was the most prevalent subtype (69.9%).
  • Higher educational attainment correlated with an increased diagnosis of MCI-MDT.
  • Extended neuropsychological evaluations (≥14 tests) showed a trend towards identifying more MCI-MDT and MCI-single domain non-amnestic (MCI-MNOA) cases, and fewer MCI-amnestic type (MCI-AT) cases, though not statistically significant.

Impact:

  • Findings suggest that MCI-MDT is the predominant MCI subtype in this population.
  • Comprehensive neuropsychological assessments are recommended for more accurate and nuanced classification of MCI subtypes.
  • This improved classification can aid in better understanding the heterogeneity of MCI and potentially guide future research and clinical management.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...